The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
LexisNexis
Advertisement
Articles by LexisNexis
Advertisement
Latest Updated Articles
- March 2017: Big Data, Big Opportunity in Life Sciences
Published: March 1st 2017 | Updated: January 22nd 2021
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Pharmaceutical Executive Daily: FDA Approves Hernexeos
3
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
4
FDA Approves Hernexeos Under National Priority Voucher Program
5